Tower Research Capital LLC TRC Increases Stock Position in Electromed, Inc. (NYSE:ELMD)

Tower Research Capital LLC TRC increased its stake in shares of Electromed, Inc. (NYSE:ELMD) by 426.6% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 5,055 shares of the company’s stock after purchasing an additional 4,095 shares during the period. Tower Research Capital LLC TRC owned approximately 0.06% of Electromed worth $149,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in ELMD. Russell Investments Group Ltd. purchased a new stake in Electromed during the 4th quarter valued at $37,000. IFP Advisors Inc bought a new position in Electromed in the fourth quarter valued at about $59,000. Quantbot Technologies LP purchased a new position in Electromed in the fourth quarter worth about $99,000. Bailard Inc. bought a new stake in shares of Electromed during the 4th quarter valued at about $224,000. Finally, Jump Financial LLC purchased a new stake in shares of Electromed during the 4th quarter valued at about $237,000. Institutional investors own 40.82% of the company’s stock.

Analysts Set New Price Targets

Several brokerages recently issued reports on ELMD. B. Riley initiated coverage on shares of Electromed in a research report on Thursday, February 20th. They set a “buy” rating and a $38.00 target price for the company. StockNews.com upgraded Electromed from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, April 30th.

Electromed Trading Down 1.1 %

Electromed stock opened at $22.38 on Wednesday. Electromed, Inc. has a 12-month low of $13.74 and a 12-month high of $35.56. The firm has a market capitalization of $191.51 million, a price-to-earnings ratio of 29.84 and a beta of 0.46. The firm has a 50 day moving average of $23.85 and a 200 day moving average of $27.41.

Electromed announced that its Board of Directors has initiated a share repurchase plan on Monday, March 10th that authorizes the company to buyback $5.00 million in shares. This buyback authorization authorizes the company to repurchase up to 2.4% of its shares through open market purchases. Shares buyback plans are generally an indication that the company’s board of directors believes its stock is undervalued.

Insider Transactions at Electromed

In other Electromed news, Director Kathleen Skarvan sold 8,640 shares of the stock in a transaction on Friday, February 14th. The stock was sold at an average price of $32.25, for a total value of $278,640.00. Following the completion of the sale, the director now owns 71,576 shares in the company, valued at approximately $2,308,326. This represents a 10.77 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Andrew Summers sold 50,751 shares of the business’s stock in a transaction dated Monday, February 24th. The shares were sold at an average price of $27.30, for a total value of $1,385,502.30. Following the completion of the transaction, the director now owns 65,714 shares in the company, valued at $1,793,992.20. The trade was a 43.58 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 133,618 shares of company stock valued at $3,821,636 over the last three months. Corporate insiders own 14.00% of the company’s stock.

About Electromed

Electromed, Inc develops, manufactures, markets, and sells airway clearance therapy and related products that apply high frequency chest wall oscillation (HFCWO) therapy in pulmonary care for patients of various ages in the United States and internationally. The company offers SmartVest airway clearance system for patients with compromised pulmonary functions, including bronchiectasis and cystic fibrosis, as well as neuromuscular conditions, such as cerebral palsy and amyotrophic lateral sclerosis; SmartVest SQL System; SmartVest Clearway System that consists of an inflatable therapy garment, a programmable air pulse generator, and a patented single-hose that delivers air pulses from the generator to the garment to create oscillatory pressure on the chest wall; and SmartVest Connect, a wireless technology that allows data connection between physicians and patients to track therapy performance and collaborate in treatment decisions.